Search hospitals > Georgia > Augusta

Augusta University Medical Center

Claim this profile
Augusta, Georgia 30912
Global Leader in Cancer
Global Leader in Leukemia
Conducts research for Ovarian Cancer
Conducts research for Recurrence
Conducts research for Tumors
247 reported clinical trials
32 medical researchers
Photo of Augusta University Medical Center in AugustaPhoto of Augusta University Medical Center in AugustaPhoto of Augusta University Medical Center in Augusta

Summary

Augusta University Medical Center is a medical facility located in Augusta, Georgia. This center is recognized for care of Cancer, Leukemia, Ovarian Cancer, Recurrence, Tumors and other specialties. Augusta University Medical Center is involved with conducting 247 clinical trials across 856 conditions. There are 32 research doctors associated with this hospital, such as Sharad Ghamande, Colleen H. McDonough, Jorge Cortes, MD, and Vamsi Kota, MD.

Area of expertise

1Cancer
Global Leader
Augusta University Medical Center has run 85 trials for Cancer. Some of their research focus areas include:
Stage IV
Stage I
Stage III
2Leukemia
Global Leader
Augusta University Medical Center has run 37 trials for Leukemia. Some of their research focus areas include:
Stage II
CD5 positive
Philadelphia chromosome positive

Top PIs

Clinical Trials running at Augusta University Medical Center

Non-Small Cell Lung Cancer
Ovarian Cancer
Cancer
Squamous Cell Carcinoma
Diffuse Large B-Cell Lymphoma
Lung Cancer
Ovarian Tumors
Lymphoma
Fallopian Tube Cancer
Ovarian Carcinoma
Image of trial facility.

Crizotinib

for Non-Small Cell Lung Cancer

This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Image of trial facility.

Repotrectinib vs Crizotinib

for Non-Small Cell Lung Cancer

This trial is testing two medications, repotrectinib and crizotinib, in patients with a specific type of lung cancer that hasn't been treated with certain drugs before. These medications work by blocking a protein that helps cancer cells grow and spread. The goal is to see if these treatments are effective and safe for these patients.
Recruiting2 awards Phase 36 criteria
Image of trial facility.

Targeted Therapy Screening

for Lung Cancer

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Augusta University Medical Center?
Augusta University Medical Center is a medical facility located in Augusta, Georgia. This center is recognized for care of Cancer, Leukemia, Ovarian Cancer, Recurrence, Tumors and other specialties. Augusta University Medical Center is involved with conducting 247 clinical trials across 856 conditions. There are 32 research doctors associated with this hospital, such as Sharad Ghamande, Colleen H. McDonough, Jorge Cortes, MD, and Vamsi Kota, MD.